Continued patient treatments in clinical trial
A further two patients were treated 3rd May in SpectraCure's clinical trial for treatment of recurrent prostate cancer at the Princess Margaret Cancer Centre in Toronto. The treatments were done with the method based on photodynamic therapy (PDT) developed by SpectraCure. As before, the treatments were performed by a team led by Drs Neil Fleshner […]
Agreement signed with the University of Pennsylvania Hospital for Clinical Study on Prostate Cancer Treatment
SpectraCure has signed an agreement with the University of Pennsylvania Hospital ("Penn Hospital") in Philadelphia, USA. The agreement concerns clinical studies for treatment of patients with recurrent prostate cancer with the company's photodynamic tumor therapy technique (PDT). Penn Hospital will be involved in the Phase 1 study that is also conducted at the Princess Margaret Cancer Center […]
The ethics committee in London gives approval to start clinical study
As previously announced, SpectraCure has received approval from Medicines & Healthcare products Regulatory Agency (MHRA) in the UK to conduct parts of the ongoing Phase 1 clinical trial for the treatment of prostate cancer in London. Now, also the regional ethics committee in London has approved the study protocol. This means that all formal requirements […]
Additional results from clinical phase 1 study
SpectraCure is conducting a Phase 1 clinical trial for the treatment of patients with relapse of prostate cancer, using the company's photodynamic therapy (PDT) technology. As previously announced, the fourth patient was treated on February 22nd at the Princess Margaret Cancer Centre in Toronto. During the follow-up after treatment, patients' PSA values are monitored on […]
Clinical results from SpectraCure’s fourth patient treatment
The fourth patient in the clinical phase 1 trial that SpectraCure is running for treatment of patients with recurrent prostate cancer was conducted, as previously communicated, on February 22th. The treatment was performed using the method for photodynamic therapy (PDT) that SpectraCure has developed. From the MRI of the prostate acquired a week after treatment, […]
British Medicines Agency MHRA approves clinical study
SpectraCure's application for completing parts of an ongoing Phase 1 clinical trial in the UK has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The study is the same Phase 1 study conducted by SpectraCure for the treatment of prostate cancer at the Princess Margaret Cancer Center in Toronto, Canada. With […]
New patient treatment in the clinical phase 1 study
The fourth patient has been treated on February 22, 2018 in the Phase 1 study conducted by SpectraCure for the treatment of patients with relapse of prostate cancer. The treatment was performed at Princess Margaret Cancer Centre in Toronto, Canada, and passed without complications and the patient is doing well. The treatment method, called Photodynamic […]
SpectraCure initiates process for change of listing
The Board of SpectraCure AB ("SpectraCure" or the "Company") has decided to initiate a process for change of listing, from AktieTorget to Nasdaq First North Premier. The company's ambition is to implement the list change to Nasdaq First North Premier during 2018. A listing on First North Premier is expected to create favorable conditions for […]
SpectraCure at G&W Capital Market Day, 2018
SpectraCures CEO Masoud Khayyami will present the company, including the status of the ongoing clinical study, at G&W Capital Market Day on February 23th, at 10:00 AM. Location: Berns Salonger, Kammarsalen, Berzelii Park, Stockholm The presentation can also be followed via webcast at https://tv.streamfabriken.com/2018-02-23-spectracure For further information, contact:SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 […]
Scientific and technical meetings at SPIE Photonics West
Staff from SpectraCure attended the SPIE’s conference BiOS – Photonics West in San Francisco in late January. Among other things, the partners of SpectraCure at the University of Pennsylvania presented results for the treatment of pleural cancer. The results confirmed that the real time-monitoring of optical properties, photosensitiser and oxygen supply during photodynamic treatment (PDT) […]
